We are live on ! Find out more
BCM

Burrage Capital Management Portfolio holdings

AUM $99.7M
1-Year Est. Return 66.05%
This Fund
S&P 500
This Quarter Est. Return
+15.05%
1 Year Est. Return
+66.05%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$99.7M
AUM Growth
-$23.7M
Cap. Flow
-$26.3M
Cap. Flow %
-26.37%
Top 10 Hldgs %
70.67%
Holding
30
New
3
Increased
3
Reduced
2
Closed
8

Top Buys

1
FOLD
Amicus Therapeutics
FOLD
+$4.88M
2
VSTM icon
Verastem
VSTM
+$2.45M
3
EPZM
Epizyme, Inc
EPZM
+$2.3M
4
RVMD icon
Revolution Medicines
RVMD
+$1.75M
5
INZY
Inozyme Pharma
INZY
+$1.27M

Top Sells

1
PLX icon
Protalix BioTherapeutics
PLX
+$9.48M
2
PTCT icon
PTC Therapeutics
PTCT
+$7.59M
3
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$5.17M
4
TVRD
Tvardi Therapeutics
TVRD
+$3.91M
5
FULC icon
Fulcrum Therapeutics
FULC
+$3.77M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PLX icon
26
Protalix BioTherapeutics
PLX
$192M
– –
-2,125,585
Closed -$9.48M
PTCT icon
27
PTC Therapeutics
PTCT
$6.52B
– –
-160,372
Closed -$7.59M
TVRD
28
Tvardi Therapeutics
TVRD
$30M
– –
-5,000
Closed -$3.91M
TCDA
29
DELISTED
Tricida, Inc. Common Stock
TCDA
– –
-658,877
Closed -$3.48M
TPTX
30
PUT
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
– –
-700
Closed -$861K
1
2

Similar funds

WCM
Weld Capital Management New York $98.8M AUM 52.83% 1-Year Est. Return
CCM
Coe Capital Management Highland Park, Illinois $106M AUM 53.24% 1-Year Est. Return
RGM
ROAM Global Management New York $117M AUM
TCM
Taal Capital Management Boston, Massachusetts $122M AUM 50.45% 1-Year Est. Return
RC
Regents Capital Hong Kong $76.8M AUM
AC
Aperimus Capital Marina Del Rey, California $62.2M AUM 47.35% 1-Year Est. Return
QVT
Quantitative Value Technologies Overland Park, Kansas $60.7M AUM
WFWM
Wechter Feldman Wealth Management Parsippany, New Jersey $143M AUM 25.17% 1-Year Est. Return

Burrage Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, Burrage Capital Management held 30 positions worth $99.7M, down 19% from $123M the previous quarter. Its ten largest holdings account for 71% of the portfolio.

Burrage Capital Management withdrew a net $26.3M in Q2 2021, closing 8 positions and reducing 2 holdings. Its most notable exit was Protalix BioTherapeutics, an estimated $9.48M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

Against the trend, Burrage Capital Management opened a new position in Amicus Therapeutics worth $4.82M.

  • Burrage Capital Management's largest Q2 2021 buy was Amicus Therapeutics: 500,000 shares worth $4.82M.
  • Burrage Capital Management added most to Epizyme, Inc in Q2 2021, an estimated $2.3M increase.
  • Burrage Capital Management's biggest Q2 2021 reduction was Turning Point Therapeutics, Inc. Common Stock, cutting an estimated $5.17M.
  • Burrage Capital Management fully exited Protalix BioTherapeutics in Q2 2021, selling an estimated $9.48M.
  • Burrage Capital Management's ten largest holdings make up 71% of its $99.7M portfolio in Q2 2021.
  • Burrage Capital Management opened 3 new positions and closed 8 in Q2 2021.
  • Burrage Capital Management's portfolio value fell 19% quarter-over-quarter to $99.7M.

Based on Burrage Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.